Caribou Biosciences, Inc.

Company overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, develops genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy in a Phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for solid tumors. It has a collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Market cap

$44M

Employees

147

Headquarters

Berkeley, CA

Website

cariboubio.com

CEO

Rachel E. Haurwitz

Listed

July 23, 2021

P/E

-0.28

Dividend yield

0.00%